 Benjamin Frank
Concepts (282)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 18 | 2026 | 1936 | 3.360 |
Why?
| | Heart Defects, Congenital | 14 | 2025 | 875 | 1.830 |
Why?
| | Ventricular Dysfunction, Left | 6 | 2022 | 374 | 1.660 |
Why?
| | Pulmonary Artery | 10 | 2025 | 1114 | 1.310 |
Why?
| | Hernias, Diaphragmatic, Congenital | 2 | 2023 | 207 | 1.290 |
Why?
| | Ventricular Dysfunction, Right | 5 | 2026 | 243 | 1.230 |
Why?
| | Fontan Procedure | 5 | 2024 | 182 | 1.200 |
Why?
| | Endothelin-1 | 2 | 2022 | 177 | 1.190 |
Why?
| | Echocardiography | 8 | 2026 | 643 | 1.110 |
Why?
| | Kynurenine | 3 | 2024 | 118 | 1.030 |
Why?
| | Cardiopulmonary Bypass | 8 | 2025 | 218 | 1.010 |
Why?
| | Tryptophan | 3 | 2024 | 188 | 0.990 |
Why?
| | Heart Ventricles | 10 | 2026 | 752 | 0.970 |
Why?
| | Cardiac Catheterization | 5 | 2025 | 537 | 0.960 |
Why?
| | Hemodynamics | 11 | 2025 | 1100 | 0.890 |
Why?
| | Infant | 23 | 2025 | 9818 | 0.890 |
Why?
| | Cardiac Surgical Procedures | 6 | 2024 | 585 | 0.890 |
Why?
| | Acetamides | 1 | 2024 | 36 | 0.860 |
Why?
| | Matrix Metalloproteinase 8 | 1 | 2023 | 8 | 0.830 |
Why?
| | Citrulline | 1 | 2024 | 45 | 0.830 |
Why?
| | Nitric Oxide | 3 | 2024 | 900 | 0.820 |
Why?
| | Pyrazines | 1 | 2024 | 88 | 0.820 |
Why?
| | Arginine | 1 | 2024 | 260 | 0.760 |
Why?
| | Blood Proteins | 2 | 2020 | 250 | 0.760 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2024 | 344 | 0.760 |
Why?
| | Aortic Coarctation | 2 | 2023 | 80 | 0.750 |
Why?
| | Heart Bypass, Right | 1 | 2022 | 17 | 0.740 |
Why?
| | Infant, Premature, Diseases | 2 | 2023 | 107 | 0.730 |
Why?
| | Child | 30 | 2026 | 22308 | 0.670 |
Why?
| | Ventricular Function, Left | 4 | 2023 | 513 | 0.670 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2020 | 67 | 0.660 |
Why?
| | Heart Diseases | 1 | 2023 | 335 | 0.650 |
Why?
| | Heart Function Tests | 1 | 2019 | 56 | 0.630 |
Why?
| | Infant, Newborn | 15 | 2025 | 6275 | 0.610 |
Why?
| | Scurvy | 1 | 2019 | 17 | 0.590 |
Why?
| | Interleukin-1 Receptor-Like 1 Protein | 1 | 2019 | 25 | 0.590 |
Why?
| | Prospective Studies | 11 | 2024 | 7739 | 0.590 |
Why?
| | Atrial Function, Right | 3 | 2025 | 14 | 0.570 |
Why?
| | Biomarkers | 8 | 2024 | 4174 | 0.570 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2019 | 119 | 0.560 |
Why?
| | Ventricular Function, Right | 4 | 2026 | 283 | 0.550 |
Why?
| | Bronchopulmonary Dysplasia | 2 | 2023 | 395 | 0.550 |
Why?
| | Diagnostic Imaging | 1 | 2020 | 326 | 0.550 |
Why?
| | Humans | 59 | 2026 | 141187 | 0.540 |
Why?
| | Pediatrics | 2 | 2024 | 1094 | 0.510 |
Why?
| | Ventricular Remodeling | 1 | 2019 | 259 | 0.510 |
Why?
| | Magnetic Resonance Imaging, Cine | 4 | 2025 | 209 | 0.450 |
Why?
| | Retrospective Studies | 15 | 2025 | 16273 | 0.440 |
Why?
| | Treatment Outcome | 11 | 2025 | 11120 | 0.440 |
Why?
| | Pain | 1 | 2019 | 781 | 0.400 |
Why?
| | Familial Primary Pulmonary Hypertension | 4 | 2022 | 198 | 0.400 |
Why?
| | Computed Tomography Angiography | 2 | 2025 | 134 | 0.400 |
Why?
| | Adolescent | 16 | 2025 | 22007 | 0.380 |
Why?
| | Predictive Value of Tests | 8 | 2026 | 2070 | 0.380 |
Why?
| | Matrix Metalloproteinase 7 | 2 | 2023 | 25 | 0.370 |
Why?
| | Hypoplastic Left Heart Syndrome | 2 | 2025 | 118 | 0.360 |
Why?
| | Male | 28 | 2025 | 69783 | 0.360 |
Why?
| | Pulmonary Veins | 2 | 2023 | 106 | 0.340 |
Why?
| | Heart Failure | 1 | 2024 | 2088 | 0.340 |
Why?
| | Hypoxia | 3 | 2024 | 1164 | 0.330 |
Why?
| | Vasodilator Agents | 2 | 2025 | 330 | 0.330 |
Why?
| | Myocardial Contraction | 3 | 2020 | 303 | 0.320 |
Why?
| | Antihypertensive Agents | 3 | 2024 | 508 | 0.320 |
Why?
| | Female | 27 | 2025 | 75515 | 0.320 |
Why?
| | Case-Control Studies | 5 | 2025 | 3588 | 0.310 |
Why?
| | Microfilament Proteins | 4 | 2003 | 132 | 0.300 |
Why?
| | Pulmonary Valve | 1 | 2010 | 93 | 0.300 |
Why?
| | Length of Stay | 4 | 2025 | 1254 | 0.300 |
Why?
| | Postoperative Complications | 5 | 2021 | 2797 | 0.280 |
Why?
| | Child, Preschool | 11 | 2025 | 11457 | 0.280 |
Why?
| | Circulatory Arrest, Deep Hypothermia Induced | 2 | 2025 | 26 | 0.270 |
Why?
| | Prognosis | 4 | 2026 | 4073 | 0.260 |
Why?
| | Arterial Pressure | 2 | 2025 | 131 | 0.260 |
Why?
| | Palliative Care | 3 | 2025 | 817 | 0.260 |
Why?
| | Magnetic Resonance Imaging | 8 | 2026 | 3709 | 0.250 |
Why?
| | Tissue Engineering | 1 | 2010 | 429 | 0.250 |
Why?
| | Vascular Stiffness | 2 | 2021 | 449 | 0.240 |
Why?
| | Morbidity | 2 | 2024 | 322 | 0.240 |
Why?
| | Stroke Volume | 3 | 2025 | 587 | 0.240 |
Why?
| | Carrier Proteins | 4 | 2003 | 740 | 0.240 |
Why?
| | Proteomics | 2 | 2023 | 1134 | 0.230 |
Why?
| | Hemorrhage | 2 | 2021 | 760 | 0.230 |
Why?
| | Multimodal Imaging | 1 | 2026 | 120 | 0.230 |
Why?
| | SOXF Transcription Factors | 1 | 2024 | 16 | 0.220 |
Why?
| | Kynurenic Acid | 1 | 2024 | 20 | 0.220 |
Why?
| | Serotonin | 2 | 2024 | 323 | 0.220 |
Why?
| | Norwood Procedures | 1 | 2025 | 29 | 0.220 |
Why?
| | Multidetector Computed Tomography | 1 | 2025 | 40 | 0.220 |
Why?
| | Graft Occlusion, Vascular | 1 | 2025 | 39 | 0.220 |
Why?
| | Echocardiography, Doppler | 1 | 2025 | 113 | 0.210 |
Why?
| | Acute Kidney Injury | 2 | 2022 | 819 | 0.210 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2023 | 28 | 0.210 |
Why?
| | History, 21st Century | 1 | 2024 | 220 | 0.200 |
Why?
| | Enterocolitis, Necrotizing | 1 | 2023 | 40 | 0.200 |
Why?
| | Vascular Resistance | 1 | 2024 | 364 | 0.200 |
Why?
| | Models, Cardiovascular | 2 | 2024 | 197 | 0.200 |
Why?
| | Stenosis, Pulmonary Vein | 1 | 2023 | 19 | 0.200 |
Why?
| | History, 20th Century | 1 | 2024 | 329 | 0.200 |
Why?
| | Infant, Extremely Premature | 1 | 2023 | 66 | 0.190 |
Why?
| | Ventricular Outflow Obstruction | 1 | 2022 | 41 | 0.190 |
Why?
| | Atrioventricular Block | 1 | 2022 | 37 | 0.190 |
Why?
| | Extracellular Matrix Proteins | 1 | 2023 | 157 | 0.190 |
Why?
| | Phenylpropionates | 1 | 2022 | 21 | 0.180 |
Why?
| | Infant, Newborn, Diseases | 1 | 2023 | 113 | 0.180 |
Why?
| | Fetal Diseases | 1 | 2023 | 181 | 0.180 |
Why?
| | Pyridazines | 1 | 2022 | 56 | 0.180 |
Why?
| | Amino Acids | 1 | 2025 | 497 | 0.180 |
Why?
| | Tissue Inhibitor of Metalloproteinases | 1 | 2021 | 19 | 0.180 |
Why?
| | Risk Factors | 5 | 2025 | 10438 | 0.180 |
Why?
| | Phosphoproteins | 1 | 2003 | 338 | 0.180 |
Why?
| | Protein Conformation | 2 | 2003 | 941 | 0.180 |
Why?
| | Ventricular Function | 1 | 2021 | 57 | 0.170 |
Why?
| | Aorta, Thoracic | 1 | 2023 | 280 | 0.170 |
Why?
| | Administration, Inhalation | 2 | 2021 | 596 | 0.170 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2003 | 614 | 0.170 |
Why?
| | Postoperative Period | 1 | 2022 | 355 | 0.170 |
Why?
| | Matrix Metalloproteinases | 1 | 2021 | 95 | 0.170 |
Why?
| | Pulmonary Atresia | 1 | 2020 | 22 | 0.160 |
Why?
| | Preoperative Period | 1 | 2020 | 142 | 0.160 |
Why?
| | Heart Atria | 1 | 2021 | 139 | 0.160 |
Why?
| | Proteome | 1 | 2024 | 483 | 0.160 |
Why?
| | Metabolomics | 3 | 2021 | 704 | 0.160 |
Why?
| | Electrophysiological Phenomena | 1 | 2019 | 58 | 0.160 |
Why?
| | Societies, Medical | 1 | 2024 | 855 | 0.150 |
Why?
| | Aortic Valve Stenosis | 1 | 2022 | 245 | 0.150 |
Why?
| | Extracellular Matrix | 1 | 2023 | 555 | 0.150 |
Why?
| | Gingiva | 1 | 2019 | 25 | 0.150 |
Why?
| | Mechanical Phenomena | 1 | 2019 | 85 | 0.150 |
Why?
| | Lung | 3 | 2023 | 4134 | 0.150 |
Why?
| | Regional Blood Flow | 1 | 2021 | 498 | 0.150 |
Why?
| | Coronary Care Units | 1 | 2018 | 23 | 0.150 |
Why?
| | Cholecalciferol | 1 | 2019 | 61 | 0.140 |
Why?
| | Pulmonary Alveoli | 1 | 2021 | 410 | 0.140 |
Why?
| | Infant, Premature | 2 | 2023 | 597 | 0.140 |
Why?
| | Intensive Care Units, Neonatal | 2 | 2018 | 268 | 0.140 |
Why?
| | Alkaline Phosphatase | 1 | 2019 | 149 | 0.140 |
Why?
| | Chest Pain | 1 | 2019 | 96 | 0.140 |
Why?
| | Transcriptome | 1 | 2025 | 1003 | 0.140 |
Why?
| | Endotoxemia | 1 | 2019 | 87 | 0.140 |
Why?
| | Endotoxins | 1 | 2019 | 220 | 0.140 |
Why?
| | Biomedical Research | 1 | 2024 | 703 | 0.140 |
Why?
| | Ascorbic Acid | 1 | 2019 | 179 | 0.130 |
Why?
| | Leg | 1 | 2019 | 235 | 0.130 |
Why?
| | Heart Transplantation | 1 | 2023 | 714 | 0.130 |
Why?
| | Cohort Studies | 2 | 2024 | 5799 | 0.130 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2018 | 593 | 0.130 |
Why?
| | Iron | 1 | 2019 | 323 | 0.130 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2021 | 772 | 0.120 |
Why?
| | Risk | 1 | 2019 | 904 | 0.120 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 1997 | 106 | 0.120 |
Why?
| | Swine | 3 | 2025 | 806 | 0.120 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1261 | 0.120 |
Why?
| | Tandem Mass Spectrometry | 1 | 2018 | 566 | 0.120 |
Why?
| | Actins | 3 | 2003 | 423 | 0.120 |
Why?
| | Dietary Supplements | 1 | 2019 | 566 | 0.110 |
Why?
| | Intubation, Intratracheal | 1 | 1997 | 286 | 0.110 |
Why?
| | Down Syndrome | 1 | 2021 | 506 | 0.110 |
Why?
| | Lung Diseases | 1 | 2021 | 794 | 0.110 |
Why?
| | Stents | 2 | 2025 | 529 | 0.110 |
Why?
| | Time Factors | 3 | 2021 | 6956 | 0.110 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 1049 | 0.100 |
Why?
| | Blood Pressure | 1 | 2019 | 1748 | 0.100 |
Why?
| | Amino Acid Sequence | 4 | 2003 | 2158 | 0.090 |
Why?
| | Molecular Sequence Data | 4 | 2003 | 2929 | 0.090 |
Why?
| | Diastole | 2 | 2022 | 141 | 0.080 |
Why?
| | Wounds and Injuries | 1 | 2019 | 891 | 0.080 |
Why?
| | Purines | 2 | 2022 | 179 | 0.080 |
Why?
| | Drainage | 1 | 2011 | 174 | 0.080 |
Why?
| | Cell Count | 1 | 2010 | 326 | 0.080 |
Why?
| | Bile Duct Neoplasms | 1 | 2011 | 114 | 0.080 |
Why?
| | Adult | 3 | 2023 | 39177 | 0.080 |
Why?
| | Anastomosis, Surgical | 2 | 2021 | 159 | 0.080 |
Why?
| | Cholestasis | 1 | 2011 | 207 | 0.070 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 2 | 2002 | 344 | 0.070 |
Why?
| | Peptide Fragments | 2 | 2003 | 698 | 0.070 |
Why?
| | Metabolome | 2 | 2021 | 366 | 0.070 |
Why?
| | Reproducibility of Results | 2 | 2025 | 3348 | 0.070 |
Why?
| | Keratan Sulfate | 1 | 2006 | 1 | 0.060 |
Why?
| | Histidine | 2 | 2003 | 65 | 0.060 |
Why?
| | Synovial Fluid | 1 | 2006 | 73 | 0.060 |
Why?
| | Protein Folding | 3 | 2002 | 278 | 0.060 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2006 | 139 | 0.060 |
Why?
| | Circular Dichroism | 2 | 2002 | 148 | 0.060 |
Why?
| | Age Factors | 2 | 2025 | 3292 | 0.060 |
Why?
| | Organ Specificity | 1 | 2025 | 312 | 0.050 |
Why?
| | Hyaluronic Acid | 1 | 2006 | 226 | 0.050 |
Why?
| | Vena Cava, Inferior | 1 | 2024 | 74 | 0.050 |
Why?
| | Language Development | 1 | 2024 | 69 | 0.050 |
Why?
| | Syndrome | 1 | 2024 | 378 | 0.050 |
Why?
| | Erythrocyte Membrane | 1 | 2003 | 53 | 0.050 |
Why?
| | Osteoarthritis | 1 | 2006 | 198 | 0.050 |
Why?
| | Models, Molecular | 3 | 2003 | 1603 | 0.050 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2020 | 3776 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2010 | 2504 | 0.050 |
Why?
| | Serine | 1 | 2003 | 148 | 0.050 |
Why?
| | Binding Sites | 2 | 2003 | 1316 | 0.050 |
Why?
| | Protein Structure, Tertiary | 2 | 2002 | 859 | 0.050 |
Why?
| | Molecular Structure | 1 | 2003 | 503 | 0.050 |
Why?
| | Pulmonary Circulation | 1 | 2024 | 438 | 0.050 |
Why?
| | Tadalafil | 1 | 2022 | 7 | 0.050 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 2002 | 85 | 0.050 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2022 | 36 | 0.050 |
Why?
| | Phenylalanine | 1 | 2002 | 67 | 0.050 |
Why?
| | Endothelium-Dependent Relaxing Factors | 1 | 2021 | 16 | 0.040 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2002 | 188 | 0.040 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2002 | 377 | 0.040 |
Why?
| | Amino Acid Substitution | 1 | 2002 | 310 | 0.040 |
Why?
| | Niacinamide | 1 | 2021 | 82 | 0.040 |
Why?
| | Methionine | 1 | 2021 | 159 | 0.040 |
Why?
| | Diabetic Cardiomyopathies | 1 | 2020 | 34 | 0.040 |
Why?
| | Patient-Specific Modeling | 1 | 2020 | 42 | 0.040 |
Why?
| | Systole | 1 | 2020 | 174 | 0.040 |
Why?
| | Survival Rate | 2 | 2011 | 1970 | 0.040 |
Why?
| | Gestational Age | 1 | 2023 | 957 | 0.040 |
Why?
| | Computer Simulation | 1 | 2024 | 1015 | 0.040 |
Why?
| | Coronary Circulation | 1 | 2020 | 136 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2020 | 194 | 0.040 |
Why?
| | Aortic Valve | 1 | 2022 | 359 | 0.040 |
Why?
| | Phosphorylation | 1 | 2003 | 1768 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2002 | 672 | 0.040 |
Why?
| | Time | 1 | 2019 | 87 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2022 | 1040 | 0.040 |
Why?
| | Electrocardiography | 1 | 2022 | 618 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2020 | 453 | 0.040 |
Why?
| | Animals | 5 | 2025 | 37657 | 0.040 |
Why?
| | Myocardium | 1 | 2023 | 928 | 0.040 |
Why?
| | Electrophysiologic Techniques, Cardiac | 1 | 2018 | 76 | 0.030 |
Why?
| | Aorta | 1 | 2020 | 421 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2025 | 1764 | 0.030 |
Why?
| | Pilot Projects | 1 | 2023 | 1820 | 0.030 |
Why?
| | Nevada | 1 | 1997 | 8 | 0.030 |
Why?
| | Escherichia coli | 1 | 2002 | 838 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2025 | 2892 | 0.030 |
Why?
| | Poisson Distribution | 1 | 1997 | 77 | 0.030 |
Why?
| | United States | 2 | 2025 | 15220 | 0.030 |
Why?
| | Blood Flow Velocity | 1 | 2018 | 412 | 0.030 |
Why?
| | Arthritis, Rheumatoid | 1 | 2006 | 1176 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2020 | 739 | 0.030 |
Why?
| | Confidence Intervals | 1 | 1997 | 329 | 0.030 |
Why?
| | Liver | 1 | 2025 | 1819 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 1597 | 0.030 |
Why?
| | Imaging, Three-Dimensional | 1 | 2018 | 567 | 0.030 |
Why?
| | Intensive Care Units, Pediatric | 1 | 1997 | 270 | 0.030 |
Why?
| | Kidney | 1 | 2022 | 1482 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2018 | 924 | 0.030 |
Why?
| | Oxygen | 1 | 2018 | 993 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2023 | 2746 | 0.020 |
Why?
| | Retreatment | 1 | 2011 | 73 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2021 | 5200 | 0.020 |
Why?
| | Chickens | 2 | 2002 | 189 | 0.020 |
Why?
| | Catheterization | 1 | 2011 | 182 | 0.020 |
Why?
| | Radiography, Interventional | 1 | 2011 | 122 | 0.020 |
Why?
| | Incidence | 1 | 1997 | 2794 | 0.020 |
Why?
| | Risk Assessment | 1 | 2018 | 3490 | 0.020 |
Why?
| | Bone Morphogenetic Protein 7 | 1 | 2006 | 12 | 0.020 |
Why?
| | Protein Binding | 2 | 2002 | 2239 | 0.010 |
Why?
| | Reference Values | 1 | 2006 | 805 | 0.010 |
Why?
| | Young Adult | 1 | 2020 | 13673 | 0.010 |
Why?
| | Autoantigens | 1 | 2006 | 422 | 0.010 |
Why?
| | Knee Joint | 1 | 2006 | 408 | 0.010 |
Why?
| | Chromatography, Gel | 1 | 2002 | 131 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2002 | 336 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2002 | 391 | 0.010 |
Why?
| | Plasmids | 1 | 2002 | 365 | 0.010 |
Why?
| | Cytoskeleton | 1 | 2002 | 194 | 0.010 |
Why?
| | Titrimetry | 1 | 1999 | 12 | 0.010 |
Why?
| | Consensus Sequence | 1 | 1999 | 74 | 0.010 |
Why?
| | Static Electricity | 1 | 1999 | 113 | 0.010 |
Why?
| | Solvents | 1 | 1999 | 112 | 0.010 |
Why?
| | Amino Acid Motifs | 1 | 1999 | 225 | 0.010 |
Why?
| | Ultraviolet Rays | 1 | 2002 | 401 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2011 | 7856 | 0.010 |
Why?
| | Temperature | 1 | 2002 | 669 | 0.010 |
Why?
| | Protein Structure, Secondary | 1 | 1999 | 368 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2002 | 1357 | 0.010 |
Why?
| | Kinetics | 1 | 2002 | 1652 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1999 | 556 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2002 | 2064 | 0.010 |
Why?
| | Thermodynamics | 1 | 1999 | 424 | 0.010 |
Why?
| | Software | 1 | 2002 | 676 | 0.010 |
Why?
| | Aged | 1 | 2011 | 24574 | 0.010 |
Why?
| | Middle Aged | 1 | 2011 | 34434 | 0.000 |
Why?
|
|
Frank's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|